Athena Neurosciences, Inc.

South San Francisco, CA 94080

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $0.0
First Award Date 03/01/89
Most Recent Award Date 09/01/91

Key Personnel

Last Name Name Awards Contact
Schenk Dale B Schenk 4
John Varghese John 1
Porter Seth Porter 2
Esch Frederick S Esch 1
Fritz Lawrence C Fritz 1

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/91 - 08/31/92

Alzheimer's disease is currently thought to affect as many as 1-3 million people in the USA alone. It has recently been found that the core A4 peptide of the senile plaques (one hallmark of the disease) is derived from a precursor protein 695-750 amino acids long. It is not known how the conversion of the precursor to the A4 protein occurs, bu...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/91 - 06/30/92

In the coming years, the treatment of neurological disorders will be largely dependent on the development of new therapeutic agents and the modification of those compounds already in existence. The blood-brain barrier keeps most drugs out of the brain and severely limits their usefulness. Pharmaceutical companies will, therefore, need to scree...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/90 - 08/31/91

Alzheimer's disease is currently thought to affect as many as 1-3 million people in the USA alone. It has recently been found that the core A4 peptide of the senile plaques (one hallmark of the disease) is derived from a precursor protein 695-750 amino acids long. It is not known how the conversion of the precursor to the A4 protein occurs, bu...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/15/90 - 06/30/91

In the coming years, the treatment of neurological disorders will be largely dependent on the development of new therapeutic agents and the modification of those compounds already in existence. The blood-brain barrier keeps most drugs out of the brain and severely limits their usefulness. Pharmaceutical companies will, therefore, need to scree...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/89 - 12/31/89

The poor prognosis associated with brain neoplasms is a significant health problem in the United States. Current chemotherapeutic approaches have been limited by the inability to achieve therapeutic concentrations in the brain. Cyclophosphamide is unique among widely used chemotherapeutic agents in that it and its chemotherapeutically active m...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/89 - 10/31/89

Alzheimer's disease is currently thought to affect as many as 1-3 million people in the USA alone. It has recently been found that the core A4 peptide of the senile plaques (one hallmark of the disease) is derived from a precursor protein 695-750 amino acids long. It is not known how the conversion of the precursor to the A4 protein occurs, bu...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/17/89 - 09/16/89

The barrier to diffusion and transport of substances from the blood into the brain is denoted the blood-brain barrier. The blood-brain barrier severely limits delivery to the brain of drugs that could be beneficial for treatment of central nervous system (CNS) diseases. Current methods for testing drug access to the brain are time consuming, i...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/15/89 - 09/15/89

The objective of the proposal is to define antigens in the CSF that are specific to Alzheimer's disease. This effort has two important potential results. The first is a CSF-based diagnostic immunoassay for use as both a diagnostic marker and as a useful adjunct to monitor eventual therapy. The methodology to identify the diagnostic markers in...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/89 - 08/31/89